INTREPID Alliance Reveals Antiviral Pipeline Gaps

The INTREPID Alliance released its fifth Antiviral Clinical and Preclinical Development Landscape report, revealing critical gaps in the global pipeline of small-molecule antiviral treatments for 14 high-risk viral families. The analysis shows only 8 viral disease indications in clinical evaluation across 6 families, with no novel antiviral activity in 3 families (Adenoviridae, Hantaviridae, Peribunyaviridae). While preclinical efforts have increased, significant R&D investment and policy changes are urgently needed to incentivize innovation and fill these gaps. Entities like the United States — National Institutes of Health, United States — Biomedical Advanced Research and Development Authority, International — European Commission, and Novo Nordisk Foundation are providing some funding, but more long-term strategic approaches, such as stockpiling and advance purchase agreements, are lacking. James Anderson and Kelly Chibale emphasized the ongoing vulnerability to viral threats and the importance of collaborative efforts to strengthen global health security.